MyChesCo on MSN18d
Teleflex Acquires BIOTRONIK’s Vascular Intervention Business in $760 Million Deal
Teleflex Incorporated (NYSE: TFX) has announced its agreement to acquire BIOTRONIK’s Vascular Intervention business in a transaction valued at approximately €760 million. With this strategic ...
The National Law Review19d
Teleflex to Acquire BIOTRONIK’s Vascular Intervention Business
the novel PK Papyrus™ Covered Coronary Stent for acute coronary artery perforations, and the Orsiro™ Mission Drug Eluting Stent, an ultrathin drug-eluting stent with differentiated clinical ...
MassDevice19d
Biotronik shifts strategy to focus on implantable devices
Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to Teleflex.
Nasdaq19d
Teleflex Incorporated Announces Definitive Agreement to Acquire Vascular Intervention Business from BIOTRONIK for €760 Million
the novel PK Papyrus™ Covered Coronary Stent for acute coronary artery perforations, and the Orsiro™ Mission Drug Eluting Stent, an ultrathin drug-eluting stent with differentiated clinical ...
manilatimes20d
Teleflex to Acquire BIOTRONIK's Vascular Intervention Business
In coronary vascular interventions, key products include the Pantera™ Lux™ Drug-Coated Balloon Catheter, the novel PK Papyrus™ Covered Coronary Stent for acute coronary artery perforations, and the ...
Endovascular Today20d
Teleflex to Acquire Biotronik’s Vascular Intervention Business
the PK Papyrus covered coronary stent for acute coronary artery perforations; and the ultrathin Orsiro Mission drug-eluting stent For peripheral interventions, the Passeo-18 Lux peripheral drug-coated ...
jnis.bmj26d
The River study: the first prospective multicenter trial of a novel venous sinus stent for the treatment of idiopathic intracranial hypertension
Background The River stent is the first stent specifically designed for intracranial venous sinuses. We report the 1-year results of the River trial, performed to obtain Humanitarian Device Exemption ...
Endovascular Today27d
Serenity’s River Venous Sinus Stent Studied to Treat Idiopathic Intracranial Hypertension
According to the company, the trial evaluated the company’s River venous sinus stent for the treatment of idiopathic intracranial hypertension (IIH) in patients who are refractory or intolerant to ...